17 April 2024
Elston Quarterly Portfolio Update Q2 2024
In this video, Portfolio Manager David Seager provides his perspective on the key questions discussed in the recent quarterly asset allocation meeting. Read more
17th January 2022 - Asset Management
This article was originally published on LivewireMarkets.com on January 17th, 2022
Finding those emerging blue-chip companies that offer the prospect of lower risk, higher growth and a safe haven to escape volatility isn’t easy.
But as Elston portfolio manager Leon de Wet points out, digging a little deeper to understand a company really isn’t enough. You’ve really got to keep chipping away to unearth all the obstacles, and discover the bedrock of future success.
We asked de Wet to provide his view on the characteristics most likely to make a leader. Based on his experience with the Elston Australian Large Companies A portfolio, Leon was also able to identify a stock that he believes is overvalued – and nominate two interesting blue-chip picks for 2022 and beyond.
Defining an emerging market leader can be hard, but for de Wet the characteristics for any emerging blue-chip are clear:
“In essence an emerging ‘blue-chip’ company is one expected to be able to ‘stand the test of time’, to adapt to the changing competitive environment and grow earnings faster than the broader market in the years ahead.”
He cautions that while such companies often appear less risky, making them look like a sound choice for more volatile times, there is no such thing as a sure thing in equity investing – as his picks make clear.
A case in point for de Wet is Fisher & Paykel Healthcare (ASX:FPH), which has underperformed the market this year despite making gains from its two product groups (hospital and homecare), leaving the business at what he calls an ‘unreasonable price’.
On paper, FPH appears well placed to deliver strong revenue and growth over the next decade owing to the characteristics mentioned – including its “proven history of profit growth, net cash on balance sheet, and strong EBIT margins (c.29% pre-pandemic).”
FPH has also had the advantage of a large addressable market for its hospital and homecare products (which includes everything from humidifiers and ventilation machines to consumables like masks), giving it a leading position in the current environment.
So why does de Wet think this stock is overvalued? As for many healthcare companies, FPH benefitted from the demand for oxygen devices during COVID’s height, but that scenario may be short-lived.
“To their credit, management have done an outstanding job of ensuring supply of the lifesaving equipment – the result, in FY21 the hospital segment’s revenue increased by nearly 90% and group profit margins expanded well above management’s medium-term target given the benefits of operating leverage. For some context, hospital operating revenue grew to what we expect will be a 6-month peak (for the next few years at least), of $817.1m in 2H21 from $353.6m in 1H20.”
And while it’s clearly too early to make a call on Omicron’s long-term impact, the latest 1H22 result for FPH – $670.2m from hospital operating revenue and lower sales across the US and Europe – illustrate the predicted slowdown in hospitalisations and acute care as vaccination rates rise.
“Over the next 18-24 months we expect both sales and margins to drop further as vaccination levels improve globally, and that FY24 will deliver a profit still below that enjoyed in FY21. Trading at a little over 40x our expected FY24 earnings, FPH looks overvalued.”
de Wet points to two companies that have what it takes to become future leaders.
The first is Cochlear (ASX:COH), another well-known healthcare provider which has already taken a clear market leader position in implantable hearing solutions. According to de Wet, Cochlear has a long reach in providing both better quality of life measures and societal benefits from increased productivity.
“The addressable market is certainly underpenetrated with estimates suggesting less than 5% of people suffering from severe to profound hearing loss have a hearing implant currently – so a very long runway supporting future growth.”
Additionally, the Services business segment which provides sound processor upgrades and other accessories to existing implant customers has very high switching costs, providing growing long-term annuity-style revenues as the installed base increases. Also, as noted, it is the industry leader and with its annual investment in R&D materially higher than key competitors (typically around 13% of revenue), we expect it will continue to lead in innovation and product development.”
Finally, in terms of financial metrics, it currently has a historic high net cash balance, strong EBIT margins (FY22 c. 22%) and operating cash flow sufficient to fund investing and capex requirements.”
The second (and more contentious) choice from de Wet is Amcor (ASX:AMC).
While Amcor’s Flexibles division generated “around 68% of group revenue in FY21 (the balance being from Rigids and cartons)”, an increasing ESG (environmental and social governance) focus from investors provides some pause around the company’s future decisions on plastic packaging.
Much depends on management’s choices going forward, says de Wet. And there is no easy choice – plastic packaging is critical for many industries, including healthcare, and Amcor uses plastics for 95%+ of its product streams.
“Following the Bemis acquisition in 2019, Amcor has a truly global footprint and enjoys market leadership and operating scale – it is the largest packaging company in both Europe and the US.
With a continued focus on R&D we believe Amcor is well placed to deliver a first-mover advantage in cost-effective responsible packaging, an enormous opportunity if management can execute on their pledge to develop all packaging to be recyclable or reusable by 2025.
Despite low-to-mid single digit revenue growth (excluding bolt-on M&A), strong operating cash flow (FY21 delivered c.US$1.45bn) allows not only for a consistent dividend, but also ongoing capital management (buybacks) that is ultimately EPS accretive.”
As ESG measures become more important, de Wet believes we shouldn’t discount Amcor’s prospects when change is achieveable.
If you would like more information please call 1300 ELSTON or contact us to speak to the Asset Management team.
17 April 2024
In this video, Portfolio Manager David Seager provides his perspective on the key questions discussed in the recent quarterly asset allocation meeting. Read more
10 April 2024
Elston Portfolio Manager Gary Merkel has picked three constituents of the ASX Small Ordinaries Index in the latest Livewire article. Read more
25 March 2024
Just before Easter, Livewire asked four fundies to pick which businesses they thought had the hop on some of the others in their investment universe. Read more
18 March 2024
Following on from the reporting season, Co-Founder and Portfolio Manager Bruce Williams has provided a brief overview of the recent results and what that indicates for the portfolio positioning. Read more
31 January 2024
The Australian Financial Review has recently named Elston Australian Emerging Leaders in their top performers 2023. Read the article to find out more. Read more
18 January 2024
In this video, Portfolio Manager Leon de Wet provides his perspective on the key questions discussed in the recent quarterly asset allocation meeting. Read more
1 December 2023
HUB24 announced the launch of a new whitepaper, ‘Directing the matrix: meeting the advice needs of high net worth clients’. Read now to get insights from Elston Head of Philanthropic Services Susan Chenoweth and many other experienced advisers. Read more
8 November 2023
Investing in what you are passionate about, or even what you consume everyday, can give you an edge. Find out what local stock Elston Co-Founder Bruce Williams has in mind. Read more
13 October 2023
What should advisers think about as they move to managed portfolios? Elston Head of Adviser Services Mark Smith shared his views on how to successfully make the transition. Read more
4 October 2023
We all know Australia is the lucky country, but could it soon be the luckiest? Elston Co-founder Andrew McKie believes it may be possible, and advisers need to take heed. Read more
21 September 2023
Andrew McKie joined 5 other industry leaders at LiveWire Live 2023 as they presented their shocking prediction for the future. What did he predict? And is it good news or bad news? Read more
14 September 2023
Portfolio Manager Leon de Wet has provided a brief overview of the recent reporting season results and what that indicates for future earnings and the portfolio positioning. Read more
25 August 2023
Are our two big supermarkets worth checking out? Read the latest Livewire Markets article to see what Elston Co-Founder and Portfolio Manager Bruce Williams thinks. Read more
12 August 2023
Should investors buy AMP or bypass it? See what Elston co-founder and portfolio manager Andrew McKie thinks and find out how he’s feeling about the ASX100 in general. Read more
1 August 2023
In this video, Portfolio Manager Leon de Wet provides his perspective on the key questions discussed in the recent quarterly asset allocation meeting. Read more
31 July 2023
What makes Carsales such an attractive stock? Elston Portfolio Manager Bruce Williams examines the key drivers that are working for this digital marketplace both here and overseas. Read more
26 July 2023
Last year, some bond indices fell into a black hole. Are good returns from fixed income investing still a galaxy far, far away? Or are there brighter days on the horizon? Read more
23 July 2023
In the latest Livewire's edition of Buy Hold Sell, Andrew McKie talked about which ASX-listed stocks he would want to own (or not own) in a Goldilocks scenario. Read more
20 July 2023
Elston Co-Founder Andrew McKie sat down with Han Lee from Livewire and Rob Crookston from WILSONS to discuss how they find “quality” companies on the ASX. Read more
15 July 2023
Andrew McKie was asked to analyse three stocks that are widely perceived to have those rock-solid qualities and assess whether they have become overcrowded, and name one quality company in the recent Livewire interview. Read more
12 July 2023
If you had a spare $10,000, how would you invest it? It's an interesting hypothetical and one that Elston Portfolio Manager Leon De Wet was happy to answer for Livewrire. Read the article to see his picks. Read more